Funders › NY › Emerald Foundation Inc Co Solomon Blum Heymann › 2024
Grants paid by Emerald Foundation Inc Co Solomon Blum Heymann, tax year 2024
EIN 13-3912580 · New York, NY · Form 990-PF, Part XV · NTEE T20J
In tax year 2024, Emerald Foundation Inc Co Solomon Blum Heymann (EIN 13-3912580) reported 21 grants paid totaling $1,112,500. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2024
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Massachusetts Institute of Technolo Cambridge, MA | C | $87,500 | paid | To study how ferroptosis-based strategies can enhance the efficacy of immunotherapies in breast cancer. | 202522949349100217 |
| 2024 | University of Maryland Sch of Medic Baltimore, MD | U | $75,000 | paid | TO INVESTIGATE THE REGULATION OF TREG LYMPHATIC TUMOR MIGRATION AND THE INTERACTION AMONG TREGS, LYMPHATIC ENDOTHELIAL CELLS, AND TUMORS TO DEVELOP STRATEGIES OF DELIVERING TARGETED THERAPIES LOCALLY INSTEAD OF SYSTEMICALLY. | 202522949349100217 |
| 2024 | Nyu School of Medicine New York, NY | U | $75,000 | paid | To examine the cellular mechanisms through which dendrite-centric Alzheimer's disease pathologies result in cognitive dysfunction and hyper-excitability. | 202522949349100217 |
| 2024 | University of Maryland Sch of Medic Baltimore, MD | U | $75,000 | paid | To investigate the regulation of Treg lymphatic tumor migration and the interaction among Tregs, lymphatic endothelial cells, and tumors to develop strategies of delivering targeted therapies locally instead of systemically. | 202522949349100217 |
| 2024 | Massachusetts Institute of Technolo Cambridge, MA | C | $75,000 | paid | To enhance nanoparticle accumulation in desired cell types to develop more effective and safer targeted nanotherapies. | 202522949349100217 |
| 2024 | Dana-Farber Cancer Institute Boston, MA | B | $50,000 | paid | To map the transcriptional and protein changes induced by lactate and identify the mechanisms that cause NK suppression, on both NK and tumor cells, using high-throughput and unbiased approaches. | 202522949349100217 |
| 2024 | University of Pennsylvania Philadelphia, PA | U | $50,000 | paid | To understand the molecular mechanism underlying immunosuppression and immunoactivation and develop new treatment strategies for hepatic malignancies. | 202522949349100217 |
| 2024 | Salk Institute for Bio Studies La Jolla, CA | C | $50,000 | paid | To use innovative cell biology techniques coupled with genomics to investigate the role of mitochondrial-derived vesicles in cancer cell metabolism. | 202522949349100217 |
| 2024 | Salk Institute for Biological Studi La Jolla, CA | C | $50,000 | paid | TO USE INNOVATIVE CELL BIOLOGY TECHNIQUES COUPLED WITH GENOMICS TO INVESTIGATE THE ROLE OF MITOCHONDRIAL-DERIVED VESICLES IN CANCER CELL METABOLISM. | 202522949349100217 |
| 2024 | University of Kentucky Lexington, KY | C | $50,000 | paid | To understand how maladaptive changes to the integrated stress response pathway alter the force generating ability of human heart cells and determine if pharmacological manipulation can rescue cardiomyocyte function. | 202522949349100217 |
| 2024 | Dana-Farber Cancer Institute Boston, MA | B | $50,000 | paid | To map the transcriptional and protein changes induced by lactate and identify the mechanisms that cause NK suppression, on both NK and tumor cells, using high-throughput and unbiased approaches. | 202522949349100217 |
| 2024 | John Hopkins University Baltimore, MD | U | $50,000 | paid | To investigate how the colon microbiota and host genetics intersect to alter responsiveness to immunotherapy in colorectal cancer. | 202522949349100217 |
| 2024 | University of Kentucky Lexington, KY | C | $50,000 | paid | TO UNDERSTAND HOW MALADAPTIVE CHANGES TO THE INTEGRATED STRESS RESPONSE PATHWAY ALTER THE FORCE GENERATING ABILITY OF HUMAN HEART CELLS AND DETERMINE IF PHARMACOLOGICAL MANIPULATION CAN RESCUE CARDIOMYOCYTE FUNCTION. | 202522949349100217 |
| 2024 | University of Michigan Ann Arbor, MI | U | $50,000 | paid | To use tumor organoid and mouse models to determine how loss of Claudin proteins impacts tumor invasion and metastasis. | 202522949349100217 |
| 2024 | University of Pennsylvania Philadelphia, PA | U | $50,000 | paid | To understand the molecular mechanism underlying immunosuppression and immunoactivation and develop new treatment strategies for hepatic malignancies. | 202522949349100217 |
| 2024 | Who We Play for Inc Cocoa Beach, FL | C | $37,500 | paid | To screen young students for previously undiagnosed heart ailments and generate data that can be used to train AI programs to better evaluate electrocardiograms. | 202522949349100217 |
| 2024 | Fox Chase Cancer Center Philadelphia, PA | C | $37,500 | paid | To investigate the role of Brg1-dependent epigenetic regulation on PDAC fibroblast pro-tumorigenic functions. | 202522949349100217 |
| 2024 | Harvard Medical School Boston, MD | U | $37,500 | paid | To study how SLC7A5 regulates metabolic reprogramming and signaling pathways that enable cancer cells to survive CDK4/6i treatment. | 202522949349100217 |
| 2024 | Nyu School of Medicine New York, NY | U | $37,500 | paid | To characterize interactions between proteins that associate only with the KRAS4A isoform to identifying pathways that can be rationally targeted to achieve a more comprehensive interruption of KRAS stimulation. | 202522949349100217 |
| 2024 | John Hopkins University Baltimore, MD | U | $37,500 | paid | To use tumor organoid and mouse models to determine how loss of claudin proteins impacts tumor invasion and metastasis. | 202522949349100217 |
| 2024 | Harvard Medical School Boston, MA | D | $37,500 | paid | To study how SLC7A5 regulates metabolic reprogramming and signaling pathways that enable cancer cells to survive CDK4/6i treatment. | 202522949349100217 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.